As therapeutic strategies that block the RAS using ACE inhibitors or Ang II receptor blockers are first line therapy in hypertension, experimental studies are needed that combine ACE2 activators/recombinant ACE2 with RAS blockers to determine if this approach offers incremental benefits. The gene discussed is ACE; the disease is Hypertension.